Triple negative breast cancer

Triple negative breast cancer (TNBC) is a subtype of breast cancer that is characterized by the absence of three receptors: estrogen, progesterone, and HER2. These receptors are typically targeted in breast cancer treatment, so their absence makes TNBC more difficult to treat.

Overview

TNBC accounts for approximately 15-20% of all breast cancers. It is more common in women under the age of 40, in African American women, and in those with a BRCA1 mutation. TNBC is more aggressive than other types of breast cancer, with a higher likelihood of recurrence and a poorer prognosis.

Diagnosis

Diagnosis of TNBC is made through a biopsy, which is then tested for the presence of estrogen, progesterone, and HER2 receptors. If all three are absent, the cancer is classified as triple negative.

Treatment

Treatment for TNBC typically involves a combination of surgery, chemotherapy, and radiation therapy. Because TNBC lacks the three receptors that are commonly targeted in breast cancer treatment, it is less responsive to hormonal therapy and HER2-targeted drugs.

Research

Research into TNBC is ongoing, with a focus on finding new treatment options. Current research areas include immunotherapy, PARP inhibitors, and androgen receptor-targeted therapy.

See also

• Breast cancer
• Estrogen receptor
• Progesterone receptor
• HER2/neu

Triple negative breast cancer Resources
Latest articles Most recent articles Ongoing trials	Wikipedia